When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157 - Concepedia

Concepedia

Publication | Open Access

When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157

DOI Full Paper Access

193

Citations

32

References

2017

Year

Diego Rojas‐Rivera, Tinneke Delvaeye, Ria Roelandt, Wim Nerinckx, Koen Augustyns, Peter Vandenabeele, Mathieu J.M. Bertrand

Cell Death and Differentiation

Critical IssuesMedicineReceptor Tyrosine KinasePharmacotherapyDrug DevelopmentPharmacologyRadiation OncologyPerk InhibitorsDrug DiscoveryTranslational Pharmacology

References

	Year	Citations

Page 1

Page 1